Overview
This study aims to investigate the incidence of euphoria induced by remimazolam during gastrointestinal endoscopy and explore its related factors. Gastrointestinal endoscopy, a minimally invasive procedure, often causes discomfort and anxiety for patients. Remimazolam, a short-acting benzodiazepine, is increasingly used for sedation during these procedures due to its rapid onset, short metabolism, and controlled cardiorespiratory effects. This cross-sectional study will evaluate the effect of remimazolam on patient comfort, cooperation, and satisfaction during endoscopy, aiming to optimize sedation protocols and improve clinical outcomes.
Eligibility
Inclusion Criteria:
- Adults aged 18 to 65 years, regardless of gender.
- Patients scheduled for routine painless gastrointestinal endoscopy, including gastroscopy, colonoscopy, or both.
- ASA physical status classification: I or II.
- BMI between 18 kg/m² and 28 kg/m².
- Anticipated procedural duration of no more than 30 minutes.
- Patients who have provided written informed consent after understanding the study purpose, procedures, and potential risks.
Exclusion Criteria:
- History of psychiatric disorders such as schizophrenia, bipolar disorder, or personality disorders, or a history of alcohol, stimulant, or other substance abuse.
- Known allergies or intolerance to any medication used in the study, including remimazolam, sufentanil, or benzodiazepines.
- Patients requiring complex endoscopic procedures (e.g., ERCP, endoscopic submucosal dissection, endoscopic mucosal resection, or peroral endoscopic myotomy).
- History of severe hepatic or renal disease.
- Pregnant or lactating women.
- Participation in another clinical study within the past three months.
- Any condition or factor that, in the investigator's judgment, makes the patient unsuitable for participation in the study.